Standout Papers
Citation Impact
Citing Papers
Crippling life support for SARS-CoV-2 and other viruses through synthetic lethality
2020 StandoutNobel
PARP inhibitors: Synthetic lethality in the clinic
2017 StandoutScience
Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation
2017 Standout
Secure, privacy-preserving and federated machine learning in medical imaging
2020 Standout
Cancer immunotherapies targeting the PD-1 signaling pathway
2017 StandoutNobel
Breast cancer
2019 Standout
Triple-negative breast cancer molecular subtyping and treatment progress
2020 Standout
HIF-independent synthetic lethality between CDK4/6 inhibition and VHL loss across species
2019 StandoutNobel
Clinical implications of molecular heterogeneity in triple negative breast cancer
2015
Cancer treatment and survivorship statistics, 2022
2022 Standout
Cancer-Related Fatigue
2010
Two decades beyond BRCA1/2: Homologous recombination, hereditary cancer risk and a target for ovarian cancer therapy
2015
Trabectedin for the treatment of breast cancer
2015
Overall survival in patients with platinum-sensitive recurrent serous ovarian cancer receiving olaparib maintenance monotherapy: an updated analysis from a randomised, placebo-controlled, double-blind, phase 2 trial
2016
Pancreatic cancer
2020 Standout
PARP inhibitors for BRCA1/2-mutated and sporadic ovarian cancer: current practice and future directions
2016
Mechanisms and strategies to overcome chemotherapy resistance in metastatic breast cancer
2008
Cochrane reviews of educational and self-management interventions to guide nursing practice: A review
2008 Standout
Genetic epidemiology of ovarian cancer and prospects for polygenic risk prediction
2017
Olaparib: First Global Approval
2015
PD-1/PD-L1 and immunotherapy for pancreatic cancer
2017
Pancreatic cancer
2016 Standout
Triple-negative breast cancer: treatment challenges and solutions
2016
Hepatocellular carcinoma
2021 Standout
Searching for cancer-associated gene polymorphisms: promises and obstacles
2003
ESMO-Magnitude of Clinical Benefit Scale version 1.1
2017
Cancer-associated cachexia
2018 Standout
A machine learning algorithm predicts molecular subtypes in pancreatic ductal adenocarcinoma with differential response to gemcitabine-based versus FOLFIRINOX chemotherapy
2019
The 21-Gene Recurrence Score Assay for Node-Positive, Early-Stage Breast Cancer and Impact of RxPONDER Trial on Chemotherapy Decision-Making: Have Clinicians Already Decided?
2017
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
Preventing or reducing late side effects of radiation therapy: radiobiology meets molecular pathology
2006 Standout
Primary breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2010 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Psychosocial impact of breast cancer surgeries in chinese patients and their spouses
2003
Implementing Genome-Driven Oncology
2017
Drug development in the era of precision medicine
2017
New therapeutic strategies to treat human cancers expressing mutant p53 proteins
2018
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer
2016
Fear of cancer recurrence in adult cancer survivors: a systematic review of quantitative studies
2013 Standout
Cancer treatment and survivorship statistics, 2012
2012 Standout
Male breast cancer: is the scenario changing
2008
Fadiga relacionada ao câncer: uma revisão
2011 Standout
Early breast cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2019 Standout
Cancer-related fatigue—mechanisms, risk factors, and treatments
2014 Standout
Wound dressings – a review
2015 Standout
Development of tumor mutation burden as an immunotherapy biomarker: utility for the oncology clinic
2018 Standout
Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
2018 Standout
Bisphosphonates—much more than only drugs for bone diseases
2019
Using sulfuramidimidoyl fluorides that undergo sulfur(vi) fluoride exchange for inverse drug discovery
2020 StandoutNobel
Similar prevalence of founder BRCA1 and BRCA2 mutations among Ashkenazi and non-Ashkenazi men with breast cancer: Evidence from 261 cases in Israel, 1976–1999
2007
Cancer‐Related Fatigue: State of the Science
2010
Lipid Nanoparticles Delivering Constitutively Active STING mRNA to Stimulate Antitumor Immunity
2022 StandoutNobel
A Case of Immune‐Mediated Liver Injury Induced by Olaparib
2018
Capturing Magnesium Ions via Microfluidic Hydrogel Microspheres for Promoting Cancellous Bone Regeneration
2021 Standout
Olaparib: an oral PARP-1 and PARP-2 inhibitor with promising activity in ovarian cancer
2015
Psychosocial interventions for reducing fatigue during cancer treatment in adults
2009
Next Generation of Fluorine-Containing Pharmaceuticals, Compounds Currently in Phase II–III Clinical Trials of Major Pharmaceutical Companies: New Structural Trends and Therapeutic Areas
2016 Standout
Ovarian cancer statistics, 2018
2018 Standout
Immune checkpoint inhibition in ovarian cancer
2016
Functional Nanomaterials for Phototherapies of Cancer
2014 Standout
Breast Cancer Treatment
2019 Standout
From Genetic Alterations to Tumor Microenvironment: The Ariadne’s String in Pancreatic Cancer
2020
In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450
2017
Male Breast Cancer: A Population-Based Comparison With Female Breast Cancer
2009 Standout
Cancer treatment and survivorship statistics, 2019
2019 Standout
Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer
2021 Standout
Reactive Oxygen Species (ROS)-Based Nanomedicine
2019 Standout
Olaparib for Metastatic Castration-Resistant Prostate Cancer
2020
Angiogenic gene signature in human pancreatic cancer correlates with TGF-beta and inflammatory transcriptomes
2015
ADMETlab 2.0: an integrated online platform for accurate and comprehensive predictions of ADMET properties
2021 Standout
Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: A randomized double-blind trial
2016 Standout
Multidisciplinary Meeting on Male Breast Cancer: Summary and Research Recommendations
2010 Standout
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
2020
Effects of Psycho-Oncologic Interventions on Emotional Distress and Quality of Life in Adult Patients With Cancer: Systematic Review and Meta-Analysis
2013
Hereditary breast cancer
2001
Breast Cancer—Major changes in the American Joint Committee on Cancer eighth edition cancer staging manual
2017
Works of Georgeta Fried being referenced
Treatment decisions in estrogen receptor-positive early breast cancer patients with intermediate oncotype DX recurrence score results
2014
Living with mastectomy and breast conservation treatment: who suffers more?
1997
The 21-Gene Recurrence Score Assay (Oncotype DX™) in Estrogen Receptor-Positive Male Breast Cancer: Experience in an Israeli Cohort
2014
Efficacy and safety of olaparib monotherapy in germline BRCA1 / 2 mutation carriers with advanced ovarian cancer and three or more lines of prior therapy
2015
Significantly lower rates of BRCA1/BRCA2 founder mutations in Ashkenazi women with sporadic compared with familial early onset breast cancer
2000
Male breast carcinoma in Israel
2002
Comparing Relaxation Training and Cognitive-Behavioral Group Therapy for Women With Breast Cancer
2007
Vinorelbine/VP-16 (etoposide) in metastatic breast cancer: a phase II study.
2012
Olaparib Monotherapy in Patients With Advanced Cancer and a Germline BRCA1/2 Mutation
2014 Standout
Abstract P5-08-02: Real-life analysis evaluating 1594 N0/Nmic breast cancer patients for whom treatment decisions incorporated the 21-gene recurrence score result: 5-year KM estimate for breast cancer specific survival with recurrence score results ≤30 is >98%
2016
Oral Bisphosphonates and Improved Survival of Breast Cancer
2016